CBX-11 combines Cybrexa’s proprietary alphalex™ tumor targeting technology with an already-approved oral small molecule PARP inhibitor. CBX-11 will be evaluated in combination with DNA damaging chemotherapy for the treatment of patients with solid tumors that lack homologous recombination deficiency (HRD). The company remains on track to submit its Investigational New Drug (IND) application for CBX-11 by the fourth quarter of 2019, with a Phase 1 clinical trial evaluating CBX-11 in combination with chemotherapy anticipated to begin in the first quarter of 2020.
Details for the poster presentation are as follows:
| Targeting solid tumor acidic microenvironment with an alphalex PARP inhibitor | ||
| Permanent Abstract # 2981 / Poster #3 | ||
| Session: | Diagnostics, Biomarkers, and the Tumor Microenvironment | |
| Date and Time: | Tuesday, April 2; 8:00 am – 12:00 pm EST | |
| Location: | Georgia World Congress Center, Exhibit Hall B, Poster Section 11 | |
| Presenting Author: | Vishwas Paralkar, PhD, Chief Scientific Officer of Cybrexa | |
“This marks the...
Interested in reading more?
The Scientist ARCHIVES
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
